Immunocore Holdings plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Immunocore Holdings plc (IMCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 61.33 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 17.40K shares, a 70.06% decline year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 43.93K shares, a 512.12% increase year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 4.04K shares.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 16.99K shares.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 86.31K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 17.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 61.33K shares 10-Q · filed 2026-08-06 | 65.37K shares derived: sum of 3 quarters · filed 2026-08-06 | 82.36K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 43.93K shares 10-Q · filed 2026-05-06 | 47.97K shares derived: sum of 2 quarters · filed 2026-05-06 | 64.96K shares derived: sum of 3 quarters · filed 2026-05-06 | 123.06K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 4.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 21.03K shares derived: sum of 2 quarters · filed 2026-02-25 | 79.14K shares derived: sum of 3 quarters · filed 2026-02-25 | 86.31K shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 16.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 75.09K shares derived: sum of 2 quarters · filed 2025-11-06 | 82.27K shares 10-Q · filed 2025-11-06 | |
| 2025-06-30 | 58.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 65.28K shares 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | 7.18K shares 10-Q · filed 2025-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |